Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia

Aberrant expression of aurora kinase A is implicated in the genesis of various neoplasms, including acute myeloid leukemia. Alisertib, an aurora A kinase inhibitor, has demonstrated efficacy as monotherapy in trials of myeloid malignancy, and this efficacy appears enhanced in combination with conven...

Descripción completa

Detalles Bibliográficos
Autores principales: Fathi, Amir T., Wander, Seth A., Blonquist, Traci M., Brunner, Andrew M., Amrein, Philip C., Supko, Jeffrey, Hermance, Nicole M., Manning, Amity L., Sadrzadeh, Hossein, Ballen, Karen K., Attar, Eyal C., Graubert, Timothy A., Hobbs, Gabriela, Joseph, Christelle, Perry, Ashley M., Burke, Meghan, Silver, Regina, Foster, Julia, Bergeron, Meghan, Ramos, Aura Y., Som, Tina T., Fishman, Kaitlyn M., McGregor, Kristin L., Connolly, Christine, Neuberg, Donna S., Chen, Yi-Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395112/
https://www.ncbi.nlm.nih.gov/pubmed/28034990
http://dx.doi.org/10.3324/haematol.2016.158394

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395112/
https://www.ncbi.nlm.nih.gov/pubmed/28034990
http://dx.doi.org/10.3324/haematol.2016.158394

Ejemplares similares